205 related articles for article (PubMed ID: 17125483)
1. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.
Schiff JD; Bar-Chama N; Cesaretti J; Stock R
BJU Int; 2006 Dec; 98(6):1255-8. PubMed ID: 17125483
[TBL] [Abstract][Full Text] [Related]
2. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations.
Ohebshalom M; Parker M; Guhring P; Mulhall JP
J Urol; 2005 Jul; 174(1):258-62; discussion 262. PubMed ID: 15947650
[TBL] [Abstract][Full Text] [Related]
4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
[TBL] [Abstract][Full Text] [Related]
6. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
[TBL] [Abstract][Full Text] [Related]
7. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
[TBL] [Abstract][Full Text] [Related]
8. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.
Pahlajani G; Raina R; Jones JS; Burdick M; Ali M; Li J; Mahadevan A; Ciezki J; Zippe C
BJU Int; 2010 Nov; 106(10):1524-7. PubMed ID: 20477827
[TBL] [Abstract][Full Text] [Related]
9. Success of sildenafil for erectile dysfunction in men treated with brachytherapy or external beam radiation for prostate cancer.
Shemtov OM; Radomski SB; Crook J
Can J Urol; 2004 Dec; 11(6):2450-5. PubMed ID: 15636671
[TBL] [Abstract][Full Text] [Related]
10. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up.
Cesaretti JA; Kao J; Stone NN; Stock RG
BJU Int; 2007 Aug; 100(2):362-7. PubMed ID: 17617140
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
[TBL] [Abstract][Full Text] [Related]
12. The effect on erectile function of 103palladium implantation for localized prostate cancer.
Ponholzer A; Oismüller R; Somay C; Büchler F; Maier U; Hawliczek R; Rauchenwald M; Madersbacher S
BJU Int; 2005 Apr; 95(6):847-50. PubMed ID: 15794796
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
14. Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
Hong SK; Han BK; Jeong SJ; Byun SS; Lee SE
J Urol; 2007 Aug; 178(2):613-6. PubMed ID: 17570410
[TBL] [Abstract][Full Text] [Related]
15. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study.
Stephenson RA; Mori M; Hsieh YC; Beer TM; Stanford JL; Gilliland FD; Hoffman RM; Potosky AL
J Urol; 2005 Aug; 174(2):646-50; discussion 650. PubMed ID: 16006930
[TBL] [Abstract][Full Text] [Related]
16. Effect of sildenafil citrate treatment on serum dehydroepiandrosterone sulfate levels in patients with erectile dysfunction.
Tekdogan U; Tuncel A; Tuglu D; Basar MM; Atan A
Urology; 2006 Sep; 68(3):626-30. PubMed ID: 16979704
[TBL] [Abstract][Full Text] [Related]
17. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
[TBL] [Abstract][Full Text] [Related]
18. Defining sexual outcomes after treatment for localized prostate carcinoma.
Schover LR; Fouladi RT; Warneke CL; Neese L; Klein EA; Zippe C; Kupelian PA
Cancer; 2002 Oct; 95(8):1773-85. PubMed ID: 12365027
[TBL] [Abstract][Full Text] [Related]
19. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
Lee IH; Sadetsky N; Carroll PR; Sandler HM
J Urol; 2008 Mar; 179(3):1072-6; discussion 1076. PubMed ID: 18206926
[TBL] [Abstract][Full Text] [Related]
20. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer.
Bradley EB; Bissonette EA; Theodorescu D
BJU Int; 2004 Nov; 94(7):1003-9. PubMed ID: 15541117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
